Rani Therapeutics Holdings Inc (RANI) Options

rani...........................................https://stockcharts.com/h-sc/ui?s=RANI&p=W&b=5&g=0&id=p86431144783

ON 1.90 break

needs volume

Beautiful move,nearly straight up!

No shit,provide air cover,dei woosi no doubt

No shit,provide air cover,dei woosi no doubt

Marker Therapeutics has a nobel prize winner as a scientific advisor and isnt going anywhere
I feel like more often than not board and advisor is a con job.

Jean-Luc Butel is an external director at Takeda.

look at his website under "management philosophy"
"6. Provide "air cover" to the team and/or the individual (as long as they work hard and ethically)."

he must be really "fun" to be around...
https://www.jeanlucbutel.com/management-philosophy

board director is big executive at Takeda(Asia’s 3 largest pharma)

ZERO BORROW again,35%fee(21% last time) death hour is over,watch demand for explosion

Obesity pill(1st ever)institution buys up 117%,shares to borrow dropping

2.5m short,could see nice squeeze

RANI: Although in early stages of development, nevertheless, the incredible potential here --- for CONTRACTS with myriad big Pharma firms on a global basis to deliver not just ORAL Obesity THERAPEUTICS, but convenient ORAL treatments for many OTHER diseases --- will likely send this stock SOARING for days. (Just like @IVVD of late, which is up by 500% in the past 3-days alone.)
https://finance.yahoo.com/news/rani-therapeutics-announces-preclinical-data-210500214.html

///////////////////////////////////////////////////////////////////////////

I'm not in. The News crossed my screen. Looks good🥸

RANI first impression pretty nice
havent checked in a long time

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
- Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration -

- RT-116 was well tolerated with no serious adverse events -

- Data adds to growing body of evidence of the RaniPill® platform’s potential to enable oral delivery of multiple obesity treatments -

- Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 -

SAN JOSE, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the glucagon-like peptide-1 receptor (GLP-1) agonist semaglutide administered via the RaniPill® capsule.

Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor mimicking its activity. GLP-1 is an incretin hormone and enterogastrone that stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and reduces the production of stomach acid serving as a physiological regulator of appetite and food intake.

“We believe these data provide further validation of the RaniPill® oral delivery platform across a wide variety of injectable obesity treatments. We are encouraged to see that delivery of semaglutide via the RaniPill® capsule demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration of semaglutide at the same dose,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “The target product profile of semaglutide in the RaniPill® capsule would be once-weekly oral administration of semaglutide therapy, which we believe may be more convenient for patients and could lead to improved adherence. Overall, the totality of the preclinical data we have generated in the obesity space demonstrating the successful delivery of both single and triagonist incretin therapies gives us confidence to continue building our obesity portfolio to unlock the true value of the RaniPill® technology. Looking ahead, we are excited to begin our Phase 1 study for RT-114, Rani’s GLP-1/GLP-2 dual agonist in partnership with ProGen this year.”

Currently, semaglutide is only available as a subcutaneous injection (SC) for the treatment of obesity and is marketed in the U.S. by Novo Nordisk as WEGOVY®. Worldwide sales for WEGOVY® were approximately $3.1 billion in the first half of 2024.

“There are currently no approved orally-administered GLP-1 agonists on the market for the treatment of obesity,” said Jesper Høiland, Senior Strategic Advisor for Rani Therapeutics and former executive at Novo Nordisk. “While RYBELSUS® is an oral version of semaglutide approved to improve glycemic control in adults with type 2 diabetes mellitus, it requires daily administration at a significantly higher dose than the subcutaneous equivalent. In comparison, the RaniPill HC harnesses advanced technology to deliver the same dose as the subcutaneous injection of semaglutide with expected weekly oral administration. I believe that a convenient, once-weekly oral version of semaglutide delivered via the RaniPill HC has the potential to be transformational as a next generation treatment that would impact how obesity is treated worldwide.”

Study Design

The nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) study was conducted to examine the effects of semaglutide delivered orally via the RaniPill (RT-116) versus a subcutaneous (SC) injection comparator group.
The 2x2 crossover study was conducted in two parts with a period of 4 weeks separating the two groups to evaluate the PK, PD and safety of RT-116.
Eight canines were randomized into two groups who received 0.5mg of semaglutide delivered via oral administration of the RaniPill® HC (N=4) or subcutaneous injection (N=4).
Endpoints included plasma drug concentrations, body weight, food intake, lipid profile, and safety.
Data Highlights

Semaglutide was successfully delivered in 7 of 8 canines that received the RaniPill® capsule.
Semaglutide administered via the RaniPill® capsule was well tolerated with no serious adverse events.
Cmax, Tmax, and AUC were comparable for semglutide administered via RaniPill® capsule and subcutaneous administration of semaglutide.
Oral administration via the RaniPill® capsule demonstrated bioavailability and biological activity comparable to subcutaneous administration.
The relative bioavailability of oral semaglutide was 107% versus subcutaneous administration.
Both groups saw comparable weight loss which appeared to be driven by decreased food intake that coincided with rises in plasma drug levels thus indicating there is a PD effect to treatment.
Both groups saw comparable moderate decreases in serum triglycerides and cholesterol.
https://ml.globenewswire.com/Resource/Download/b1fecb62-a30c-4b59-9234-245cebe4e59e/rani1.jpg



Route Cmax
(ng/mL) Tmax
(days) Tlast
(days) AUClast
(ng/mL*day)
Oral (RT-116) 941 ± 90 1.3 ± 0.3 17 ± 2 3630 ± 222
SC 948 ± 120 1.3 ± 0.3 17 ± 1 3390 ± 402
All data is mean ± standard error.

https://ml.globenewswire.com/Resource/Download/d32ef495-95db-41e6-8429-a597576d5ed1/rani2.jpg

Near-Term Milestone Expectations:

Initiation of Phase 1 clinical trial of RT-114 containing a GLP-1/GLP-2 dual agonist for the treatment of obesity expected in 2025.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the expected initiation of a Phase 1 trial of RT-114 in 2025, the potential of the RaniPill® platform to enable oral delivery of multiple obesity treatments and validation of such potential through preclinical data, the target product profile of semaglutide delivered via the RaniPill® capsule, the novelty, convenience and attractiveness of a once-weekly oral semaglutide treatment for patients, Rani’s confidence to continue building an obesity portfolio, the potential of a once-weekly oral version of semaglutide in the RaniPill® capsule to deliver the same benefits as subcutaneous delivery and to impact patients’ lives, the sufficiency of Rani’s cash reserves, and future financial performance. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believe,” “would,” “potential,” “expect,” “continue” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results c

neglected
cant get no love. Had hopes once because of the oral administration GLP1 platform
people dont like needles

There are no short shares available as of 11.45 am....dont sell I believe a shore squeeze will happen today if not then in the morning

AVERAGE PRICE OF 5 ANALYSIS IS $12 $$$$$$$$$$$$

16000 SHARES ON THE BID $$$$$$$$$$ BACK OVER $3 $$$$$$$$$$$$$$$

Don't listen to woodpecker he is obvious short selling and likes to make up stories

Don't listen to woodpecker he is obvious short selling and likes to make up stories

In the course of your due diligence did you read that the company is at risk of not being able to continue as an on-going concern? This was in the 10Q from June 2024. I would also take a look at the balance sheet and income statement. There you will realize $RANI is teetering on the brink of bankruptcy. It has no product, has multi million dollar losses for the last several years the most recent one 67 million $. It is burning through its cash. Caveat Emptor...Buyer beware

investor bought the 3 mil shares at $3. its now 2.40 so we get to buy lower. great news for co as they get $10 mil. its takes money to make money. co at money making phase and employees bought big time. this is guaranteed to go up rest of week. i got my money on it and average price of 5 analysis is $12 $$$$$$$$$

So the plot thickens.. RANI was prepping itself for the share and warrant offered today to Maxim Group. RANI is running out of cash. Without revenues and no guarantee of ever having a product to sell, RANI is scrambling for the pending reality that it will be unable to run as an ongoing concern. This was noted in its 10Q to the SEC in June.

RANI Therapeutics 10Q to Securities and Exchange Commission stated that due to liquidity issues there is substantial doubt regarding the company's ability to continue as a going concern. (See link below to SEC 10Q and read page 10)

https://www.marketwatch.com/investing/stock/rani/financials/secfilings?docid=17734871

There is substantial doubt regarding the Company’s ability to continue as a going concern

The Company has incurred recurring losses since its inception, including net losses of $28.1 million for the six months ended June 30, 2024. As of June 30, 2024, the Company had an accumulated deficit of $87.2 million and for the six months ended June 30, 2024, had negative cash flows from operations of $18.4 million. As of June 30, 2024, cash, cash equivalents and marketable securities totaled $30.9 million. Based on its available cash resources and current operating plan, there is substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that its financial statements for the six months ended June 30, 2024 are issued.

Im baffled. See the post I am replying too-- was in broad daylight. And only now discovered via this stoopid Oppenheimer note LOL
I love fundamental analysis!!!! So rewarding!

oral GLP1...... boom

RANI: If Oppenheimer says so, right?????

RANI under $4

MGRX did 330% today on news of planning to distribute an oral version of GLP1 sometime in the future.
This company has the platform to produce a promising oral GLP1 option right now.

You also get some free shots at the goal in 4 other indications.

RANI under $10

wants sooo much more

shake shake the tree

RANI...HERE COMES 9.00...LOL

RANI...8 DOLLA FLOOR BEING BUILT

RANI 8 DOLLA...FORTUNE COOKIE WAS RIGHT....LMAO

RANI...LETS SEE 8 BUCKS

SOMEONE WITH BRAINS AROUND HERE

RANI...GAPPING TO 7.50...LMAO...WHAT A CALL FROM THE HOUSE OF TREND

$RANI can clear worries about GLP adm.
No sellers in consecutive sessions.

ITS RAINING AGAIN WITH RANI...IS TIM ON THIS ONE?!!

RANI...LET THEM CHASE THE ALGO FABRICATIONS WHILE WE WATCH RANI TREND TO 7.00

RANI...HERE COMES 7.00

RANI...BREAKING NEW HIGH

RANI...BREAKING 6.00...BIO BEAST!!!

RANI...ITS RAINING AGAIN

RANI...HERE WE GO

RANI....BIO MONSTER